Pretty sure that they would read peer reviewed articles an Anavex presentations and then look up related research. They wouldn't learn anything new here.
Melodrama: After devoting an entire career to perfect monoclonal antibodies to digest beta-amyloids it must not be pleasant to be confronted with Anavex science. It obviates everything in the past and the future. End of career. Go learn and do something else.
C'mon let's all back off the melodrama. A highly trained scientist has options. 1. embrace 273 and direct future research on expanding its use. 2. Look for other applications for mABs.
It's hubris and not really attractive to say that these people are so worried about their careers that they are going to be against an alz treatment that works. They are going to be cheering!
And no, they dont need to go learn and do something else.
EXACTLY RIGHT...I have (like many) sat in conf rooms filled w/science people who are both actively and intellectually in strong disagreement w/the speaker/presenter...THAT IS THE EXISTING PROCESS,,,,WE GOT THIS,..in spite of DENIAL...good science will be the winner....eventually.
Yes! And, I remember about a decade ago a biochemist I was very close to being basically mocked a conferences when he revealed he was exploring Sigma (1 and 2) compounds. The more senior researchers/biochemists told him that Sigma had already been explored in the 1970's and there was no medicinal potential in this receptor site, that he was wasting his time. This perhaps partly explains why it has taken so long for the scientific community to take notice of what is happening.